These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 24556061)

  • 21. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
    Yen TT; Miyamoto T; Asaka S; Chui MH; Wang Y; Lin SF; Stone RL; Fader AN; Asaka R; Kashima H; Shiozawa T; Wang TL; Shih IM; Tanner EJ
    Gynecol Oncol; 2018 Sep; 150(3):426-431. PubMed ID: 30126589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management.
    Abdulfatah E; Wakeling E; Sakr S; Al-Obaidy K; Bandyopadhyay S; Morris R; Feldman G; Ali-Fehmi R
    Gynecol Oncol; 2019 Sep; 154(3):467-474. PubMed ID: 31248668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
    Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
    Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
    Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
    Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis.
    Rao Q; Liao J; Li Y; Zhang X; Xu G; Zhu C; Tian S; Chen Q; Zhou H; Zhang B
    Cancer Med; 2023 Mar; 12(5):5409-5419. PubMed ID: 36341543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
    Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
    Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
    Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
    Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
    Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular genetic characterization of tamoxifen-associated endometrial cancer.
    Prasad M; Wang H; Douglas W; Barakat RR; Ellenson LH
    Gynecol Oncol; 2005 Jan; 96(1):25-31. PubMed ID: 15589576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen.
    Turbiner J; Moreno-Bueno G; Dahiya S; Sánchez-Estevez C; Hardisson D; Prat J; Oliva E; Palacios J
    Mod Pathol; 2008 Aug; 21(8):925-36. PubMed ID: 18500270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunohistochemical profile of atypical eosinophilic syncytial changes vs serous carcinoma.
    Haley SL; Malhotra RK; Qiu S; Eltorky ME
    Ann Diagn Pathol; 2011 Dec; 15(6):402-6. PubMed ID: 21855381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sporadic microsatellite instability is specific to neoplastic and preneoplastic endometrial tissues.
    Faquin WC; Fitzgerald JT; Lin MC; Boynton KA; Muto MG; Mutter GL
    Am J Clin Pathol; 2000 Apr; 113(4):576-82. PubMed ID: 10787358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent CTNNB1 or PIK3CA Mutations Occurred in Endometrial Endometrioid Adenocarcinoma With High Levels of Microsatellite Instability and Loss of MSH2/MSH6 Expression.
    Huang HN; Kuo CW; Lin MC; Mao TL; Kuo KT
    Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):284-289. PubMed ID: 30789355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
    Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
    Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathology of Endometrial Carcinoma.
    Lax SF
    Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
    Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
    Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
    Bonfitto VL; de Angelo Andrade LA
    Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary.
    Oliva E; Sarrió D; Brachtel EF; Sánchez-Estévez C; Soslow RA; Moreno-Bueno G; Palacios J
    J Pathol; 2006 Apr; 208(5):708-13. PubMed ID: 16429393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.